Literature DB >> 1898908

Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa.

H Ochi1, H Ohtsuka, S Yokota, I Uezumi, M Terashima, K Irie, H Noguchi.   

Abstract

Three stable hybridoma cell lines, IN-2A8, IN-5D6, and ZI-3A8, that secrete human monoclonal antibodies (MAbs) specific for b-type flagella of Pseudomonas aeruginosa were established by fusing peripheral blood lymphocytes from healthy volunteers with murine myeloma P3X63-Ag8.653 cells. The immunoglobulin M MAbs reacted specifically with flagellin (Mr, 52,000) by Western blotting (immunoblotting) analysis and bound specifically to clinical isolates belonging to Homma serotypes A, B, H, I, and M at frequencies of 58, 50, 46, 30, and 35%, respectively, but did not bind to any serotype E or G isolates. Overall, the MAbs bound to 31% of the clinical isolates. MAb IN-2A8 strongly protected burned mice challenged with P. aeruginosa bearing b-type flagella from death following parenteral administration of 0.1 microgram per mouse. This MAb also inhibited P. aeruginosa colony spreading in soft agar at a concentration of more than 1 microgram/ml but only slightly enhanced opsonophagocytosis by human polymorphonuclear leukocytes. A line of evidence suggests that the potent in vivo activity of MAb IN-2A8 in the burned-mouse model is likely to be caused by its inhibition of bacterial motility after binding to flagella.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1898908      PMCID: PMC257784          DOI: 10.1128/iai.59.2.550-554.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Flagellar antibody stimulated opsonophagocytosis of Pseudomonas aeruginosa associated with response to either a- or b-type flagellar antigen.

Authors:  T R Anderson; T C Montie
Journal:  Can J Microbiol       Date:  1989-09       Impact factor: 2.419

Review 2.  Clinical and immune status of burn patients.

Authors:  J L Ninnemann
Journal:  Antibiot Chemother (1971)       Date:  1987

3.  Characterization of the binding of Pseudomonas aeruginosa alginate to human epithelial cells.

Authors:  P Doig; N R Smith; T Todd; R T Irvin
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

4.  Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa.

Authors:  S J Cryz; T L Pitt; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

5.  Differentiation of the major flagellar antigens of Pseudomonas aeruginosa by the slide coagglutination technique.

Authors:  R A Ansorg; M E Knoche; A F Spies; C J Kraus
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

Review 6.  Pseudomonas aeruginosa elastase and its role in pseudomonas infections.

Authors:  B Wretlind; O R Pavlovskis
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

7.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.

Authors:  R E Hancock; L M Mutharia; L Chan; R P Darveau; D P Speert; G B Pier
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

8.  Flagellar preparations from Pseudomonas aeruginosa: animal protection studies.

Authors:  I A Holder; R Wheeler; T C Montie
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

9.  Role of pili in adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells.

Authors:  D E Woods; D C Straus; W G Johanson; V K Berry; J A Bass
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

Review 10.  The role of exotoxin A in pseudomonas disease and immunity.

Authors:  M Pollack
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec
View more
  13 in total

Review 1.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model.

Authors:  N A Barekzi; K A Poelstra; A G Felts; I A Rojas; J B Slunt; D W Grainger
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

4.  Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Authors:  Michael P Horn; Adrian W Zuercher; Martin A Imboden; Michael P Rudolf; Hedvika Lazar; Hong Wu; Niels Hoiby; Stefanie C Fas; Alois B Lang
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

5.  Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology.

Authors:  Kelli L Palmer; Lauren M Mashburn; Pradeep K Singh; Marvin Whiteley
Journal:  J Bacteriol       Date:  2005-08       Impact factor: 3.490

6.  Inhibition of motility of Pseudomonas aeruginosa and Proteus mirabilis by subinhibitory concentrations of azithromycin.

Authors:  G Molinari; P Paglia; G C Schito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

7.  Characterization of Bartonella bacilliformis flagella and effect of antiflagellin antibodies on invasion of human erythrocytes.

Authors:  D C Scherer; I DeBuron-Connors; M F Minnick
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

8.  Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat.

Authors:  W J Landsperger; K D Kelly-Wintenberg; T C Montie; L S Knight; M B Hansen; C C Huntenburg; M J Schneidkraut
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

9.  Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.

Authors:  K Oishi; F Sonoda; A Iwagaki; P Ponglertnapagorn; K Watanabe; T Nagatake; A Siadak; M Pollack; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

10.  Effects of a human antiflagellar monoclonal antibody in combination with antibiotics on Pseudomonas aeruginosa infection.

Authors:  I Uezumi; M Terashima; T Kohzuki; M Kato; K Irie; H Ochi; H Noguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.